Alejandro Cane | VP, US/IDM Vaccines and Antivirals Medical and Scientific Affairs Lead

Alejandro Cane, VP, US/IDM Vaccines and Antivirals Medical and Scientific Affairs Lead, Pfizer

Alejandro D. Cané is a Specialist in Pediatrics and Pediatric Infectious Diseases and graduated with honors from the University of Buenos Aires, Argentina. In addition, he completed a Master’s in clinical and Pharmacological Research at the Universidad Austral, Buenos Aires, Argentina and also completed the Advance Course of Vaccinology jointly organized by the Merieux Foundation, France and the University of Geneva, Switzerland.
Dr Cané has the academic responsibility of Professor of Pediatrics, Infectious Diseases and Pharmacology at the Universidad Austral, Buenos Aires, Argentina. As part of his medical qualification he completed a residency in Pediatrics and Pediatric infectious diseases at the Children’s Hospital “Ricardo Gutierrez” of Buenos Aires, Argentina. His healthcare experience in Pediatrics and Pediatrics ID and Peds Bone Marrow & Liver Trasnsplant was developed in different hospitals including the Children´s Hospital of Buenos Aires and Hospital Austral in Argentina.
Dr Cané has published over 200 articles in the field of pediatrics, infectious diseases and vaccines and has collaborated on several book publications in the same fields.
He joined Wyeth in 2006 as the Medical Manager for Vaccines and over the last 17 years Dr Cané expanded his responsibilities to cover Latin America and Canada, leading the vaccines medical team at the regional level. Moreover, from June 2016 until early 2019 he has held the position of Vaccines Scientific and Medical Affairs Lead in Emerging Markets as part of Pfizer Innovative Health. During 2019-2022 he has been North America Vaccines Scientific and Medical Affairs Lead. Since October 2022 he is responsible for US and IDM Vaccines & Antivirals Medical and Scientific Affairs team


Day 1 - November 28 @ 10:10

Keynote Panel: Navigating the future of RSV Vaccines & Therapies: Tailoring Approaches from Maternal to Adults

  • Now there are vaccines available, what is the right approach for adults vs infants & maternal? 
  • What is the optimal recommendation for use of different technologies based on the epidemiology of the disease?
  • Practical issues, health economics & policy considerations 
  • Cost-effectiveness challenges
  • Remaining needs in older adults; how to protect in the second season and beyondHow to combat vaccine fatigue with new combinations and other approaches
  • The ecosystem of respiratory tract infections in the absence of RSV

Day 2 - November 29 @ 11:50

Late-stage maternal RSV vaccine development

last published: 02/Jan/24 12:15 GMT

back to speakers